In our study, the increase in CD4+ T cells observed after combined nCRT and PD-L1 inhibitor treatment may contribute to enhanced antitumor immunity via immune surveillance and modulation of the tumor microenvironment. This evidence concerns the gene CD4 and neoplasm.